SER-252 (POZ-apomorphine)
Advanced Parkinson's Disease
Phase 1Active
Key Facts
About Serina Therapeutics
Serina Therapeutics is focused on transforming drug delivery through its innovative POZylation technology, which attaches a proprietary polymer to existing drugs to improve their performance. The company's strategy centers on applying this platform to well-characterized molecules, like apomorphine for Parkinson's, to create enhanced therapies with reduced dosing frequency and side effects. By leveraging the 505(b)(2) pathway and device partnerships, Serina aims to accelerate time to market. Its lead program, SER-252, exemplifies this approach by offering a potential best-in-class, long-acting injectable for advanced Parkinson's patients.
View full company profile